BOSTON and LONDON, Feb. 10, 2025 /PRNewswire/ -- Caldwell a law firm renowned for its expertise in intellectual property is pleased to announce its role in advising Eppendorf Group a leading provider of laboratory equipment and services for the life sciences industry This transaction has led to the creation of SciSure a global technology company serving 800+ unique organizations 550,000+ research and administrative users executed in collaboration with Taylor Wessing (Netherlands) reflects Caldwell's commitment to delivering exceptional legal support in complex and high-profile matters The transaction highlights Caldwell's depth in M&A showcasing the firm's ability to provide comprehensive led by Partner Marcus Wolter and Associates Daniel O'Brien and Bianca Lindau worked seamlessly with Taylor Wessing's Marnix Geraerts and other key legal advisors to achieve this milestone The transaction was led from the client side by Dr Global Digital & Channel Business at Eppendorf Group legal support was provided by Thomas Queen (QS+S) "This transaction underscores Caldwell's ability to navigate the intricacies of cross-border M&A in the life sciences and technology sectors," said Marcus Wolter "We are proud to have partnered with Eppendorf and our esteemed colleagues at Taylor Wessing to deliver this successful outcome." Caldwell congratulates Eppendorf, SciShield and all involved parties on this significant achievement About CaldwellCaldwell is a law firm specializing in intellectual property and corporate legal services for high-growth companies Caldwell delivers innovative legal solutions across industries Mona LucierDirector of MarketingCaldwellEmail: [email protected]Phone: (857) 496-8913 a leading global law firm specializing in intellectual property Health Care & Hospitals Computer & Electronics Acquisitions, Mergers and Takeovers Do not sell or share my personal information: Eppendorf and DataHow agreed to a strategic collaboration aimed at transforming bioprocess development by integrating DataHow’s AI-enabled analytics solution with Eppendorf’s cloud-based monitoring and analytics platform The integration of DataHowLab software within BioNsight cloud offers a streamlined journey from data generation to advanced analytics and insight enabling researchers to make informed decisions quickly and efficiently Data harmony around bioreactors is essential for enabling a robust bioprocess ecosystem noting that bioprocess engineering demands seamless convergence between research and development as well as scalable production This collaboration addresses the intricate requirements for digital services in this context “Integration and collaboration are sometimes overlooked but are crucial for the success of bioprocess projects Our solutions enable seamless data sharing and contextualization across multiple devices and locations ensuring that scientists can make meaningful comparisons and generate valuable insights,” maintains Tao Copyright © 2025 Sage Publications or its affiliates including those for text and data mining and training of large language models For uncovering how a cell population helps ensure food, liquid and acid reflux are kept out of our airway — and instead sent to our gastrointestinal tract — Laura Seeholzer is the winner of the 2024 Eppendorf & Science Prize for Neurobiology. Her findings, detailed in April in Science have motivated her to study what's happening with these cells in diseases where this critical protective reflex is compromised "These findings are crucial for understanding potentially life-saving reflexes that are activated in the airway in response to noxious stimuli," said Peter Stern For most every breath we take and most every morsel or sip we consume liquid and stomach acid are sent to the GI tract this process can go wrong — a foreign agent can get into our airway And at worst it can lead to airway blockage or aspiration pneumonia — outcomes that occur frequently in people with neurological or esophageal disorders and which are a leading cause of aspiration pneumonia and mortality in older people Scientists already know that sensory systems in the upper airway rapidly detect the things that we need to exclude from our lungs the larynx and trachea respond to foreign agents and clear them But scientists don't know if the nerve fibers in the larynx and trachea act alone Seeholzer's work uncovered another entity — neuroendocrine cells that operate in the larynx and trachea — that plays a protective role. In her prize essay, "(Don't) take my breath away," Seeholzer a postdoctoral fellow at the University of California writes that "you should thank your neuroendocrine cells the next time you clear water or acid reflux out of your airway." Neuroendocrine (NE) cells are a rare group of epithelial cells throughout the larynx and trachea They are known for their important role in repairing the airway epithelium after injury They had not been thought to be involved in airway protection because these cells are near sensory nerve fibers Seeholzer and her colleagues speculated that they could be specialized sensory cells that play a role in protecting our lungs Seeholzer said she wasn't even sure there were NE cells in the trachea and larynx when she started her work I then used that to generate a hypothesis about their importance in the airway." Her efforts involved work in cells and in mice and methods including calcium imaging "I had been studying NE cells for a year or two to figure out what they detect which could inform what they do," said Seeholzer "I performed a sequencing experiment to see what the cells expressed not many receptors were expressed that supported my hypothesis that these were sensory cells that could detect stimuli that could get into the airway and professor and chair of physiology at UCSF She explained her sequencing work was not revealing what NE cells detected "He encouraged me to step back and think about what they could be detecting and to use that to nominate substances the NE cells could be frequently exposed to." That led to an "ah-ha!" moment she describes in her essay where she changed how she set up her experiments she discovered that water and strong acid solutions (like stomach acid) very consistently activated the NE cells She then sought to understand what the water and acid did to the cells she could specifically activate NE cells in mice the mice started swallowing very quickly." Seeholzer attached a device to the mice to study related changes in breathing "I very consistently saw that activating NE cells led to swallows and to cough-like reflexes." That supported her hypothesis that NE cells were detecting water and acid to elicit protective responses in the airway She says NE cells add another layer — on top of sensory neurons researchers have previously studied — giving full protection in the airway This was further evidenced by experiments in mice in which the NE cells were knocked out This led to the airway not being fully protected against foreign threats Seeholzer wants to understand how these cells operate both in healthy humans and those with diseases Her findings suggest these cells are not functioning properly in people with dysphagia which is the inability to swallow well — a major cause of mortality "I'm really interested in looking at patients who aspirate frequently to see if there's something going on with cells there," she said "And I'm interested in looking at what happens with these cells in people who smoke There are also implications for people with refractory chronic cough "Eppendorf and the journal Science have been awarding this prestigious prize since 2002," said Axel Jahns vice president of corporate citizenship & governmental affairs at Eppendorf SE the prize has acknowledged over 70 winners and finalists who have gone on to become leading scientists in their field Seeholzer on her amazing achievement in winning this year." Seeholzer expressed how her supportive lab environment made it possible to achieve the findings she did "The lab I'm in really made all the work fun and enjoyable," she said Rosemary J. Cater is a finalist for the prize for her essay, "Food for thought." Cater received her undergraduate degree and Ph.D After completing her postdoctoral fellowship at Columbia University she started her laboratory at the University of Queensland's Institute for Molecular Bioscience in 2024 Her research uses an integrated structural biology approach to understand how nutrients obtained through the diet are transported across the blood-brain barrier Claudia Kathe is also a finalist for the prize for her essay, "Rewiring movements." Kathe received an undergraduate degree and Ph.D After completing her postdoctoral fellowship at Swiss Federal Institute of Technology Lausanne (EPFL) she started her laboratory in the Department of Fundamental Neuroscience at the University of Lausanne in 2024 Her research investigates the reorganization of neuronal networks in the spinal cord in neurological disorders and its impact on sensorimotor function Our ability to provide a voice for scientists and engineers and to advance science depends on the support from individuals like you Give together we can be a united voice for scientific progress.  Join the Eppendorf Award for Young European Investigators has honored outstanding achievements in the field of biomedical research in Europe once a year The Eppendorf Award for Young European Investigators is presented in collaboration with Nature Scientists up to the age of 35 with an advanced degree, who are conducting research in Europe, can apply from October 1, 2024 to January 15, 2025 online at www.eppendorf.com/award/application An independent jury chaired by Laura Machesky (University of Cambridge UK) will select the winner of the Eppendorf Award 2025 Information about the award, the selection criteria and past winners can be found at www.eppendorf.com/award Sign up for our newsletter This issue offers insights into Europe's fight for green solutions for a bioeconomy antimicrobial resistance and how Europe is preparing for the next pandemic Since the first antibody drug was approved back in 1986 monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics and experts are divided on whether the financing nadir has been reached or even passed There are very different figures for different types of treatments under … more ➔ Reduction and Refinement) principles developed over 60 years ago provide a framework for more humane lab animal testing and Antibody-Drug Conjugates (ADCs) have been transformative in oncology offering targeted cancer treatments that enhance efficacy while sparing healthy cells Explore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist featuring insights on their expanding applications TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe By improving the ordering process and reducing … more ➔ The global sustainable laboratory plasticware market size is estimated to grow from USD 0.47 billion in the current year to USD 2.69 billion by 2035 at a CAGR of 19% during the forecast period to 2035 Sustainable / renewable plastic labware aims to lower the dependency on traditional lab plastics which are solely derived from petrochemicals contributing significantly to plastic waste Research indicates that biomedical and scientific labs generate around 5.5 million tons of plastic waste annually This highlights the urgent need for the adoption of eco-friendly materials for the production of labware Sustainable laboratory plasticwares are produced using at least 90% certified plastic from bio-based raw materials These eco-friendly options also feature enhanced recyclability The adoption of sustainable lab consumables not only significantly reduces the ecological footprint of scientific research and industrial laboratory operations but also addresses the growing regulatory pressures and sustainability goals adopting sustainable labware maintains the highest standards of quality and performance essential in laboratory settings Examples of sustainable labware include bio-based / biodegradable laboratory plasticware ongoing innovations in laboratory plasticware and a rising focus on plastic labware sustainability the adoption of renewable / sustainable laboratory plasticwares is increasing globally the shift toward eco-friendly labware has become a necessity rather than a choice further driving the integration of sustainable practices and positioning the market for steady growth in the forthcoming years Renewable / Sustainable Laboratory Plasticware Market: Key Insights The report delves into the current state of the renewable / sustainable laboratory plasticware market and identifies potential growth opportunities within the industry Some key findings from the report include: Renewable / Sustainable Laboratory Plasticware Market: Key SegmentsRecycled Plastics based Labware is the Fastest Growing Segment of the Renewable / Sustainable Laboratory Plasticware Market Polypropylene is Likely to Dominate the Renewable / Sustainable Laboratory Plasticware Market During the Forecast Period Pipette Tips is Likely to Hold the Largest Share of the Renewable / Sustainable Laboratory Plasticware Market During the Forecast Period Academic and Research Institutes Segment is Likely to Grow at a Relatively Faster Pace During the Forecast Period Europe Accounts for the Largest Share of the Market Players in the Renewable / Sustainable Laboratory Plasticware Market Renewable / Sustainable Laboratory Plasticware Market: Research Coverage The report on renewable / sustainable laboratory plasticware market features insights into various sections SECTION V: MARKET TRENDS AND STRATEGIC TOOLS About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. a pioneer in advanced data analytics and AI-driven prediction software have announced a strategic collaboration aimed at transforming bioprocess development This partnership will integrate DataHow's innovative AI-enabled analytics solution with Eppendorf's cloud-based monitoring and analytics platform providing scientists with unparalleled insight and analytics capabilities In the highly specialized field of bioprocess development the ability to design and optimize complex processes that meet stringent quality standards with maximum efficiency is crucial Process data is a critical asset in this endeavor yet leveraging it effectively remains a significant analytical challenge for process scientists The integration of DataHowLab software within BioNsight cloud addresses this need by offering a streamlined journey from data generation to advanced analytics and insight Bioprocess engineering demands seamless convergence between research and development as well as scalable production Manual data cleaning and formatting are often tedious and error-prone tasks that can significantly impede the research process the integrated platform saves valuable time and reduces the risk of errors allowing researchers to focus on value-add analysis and in generating critical insights for decision-making This is where cloud technology truly excels DataHowLab democratizes access to advanced AI-enabled analytics enabling non-data science experts to perform complex analyses with guided workflows Scientists can use the software to perform advanced process data analytics run in silico simulations to generate insight outside of the wet lab or for AI-enabled optimal experimental design R&D can operate more efficiently by reducing experimental effort and accelerating project timelines Want the latest science news straight to your inbox? Become a SelectScience member for free today>> New to SelectScience?Register for free today The Hamburg-based life sciences company Eppendorf SE has announced the winner of its prestigious research prize for the 29th time Dr Clemens Plaschka from the Institute of Molecular Pathology (IMP) in Vienna has been awarded the Eppendorf Award for Young European Investigators 2024 chaired by Professor Laura Machesky from Cambridge selected Dr Plaschka for his ground-breaking research on the molecular machines that generate and export messenger RNA Clemens Plaschka receives the €20,000 award for his pioneering work that unveils the mechanisms behind the production and maturation of messenger RNA (mRNA) His discoveries have shed light on the complex processes that enable mRNA to be processed and exported from the nucleus to the cytoplasm The jury highlighted that Plaschka’s structural and mechanistic investigations have provided fundamental insights into gene expression and have significant implications for understanding human diseases associated with mutations in core mRNA processing machinery Clemens Plaschka said: "I am absolutely delighted to receive the 2024 Eppendorf Award for Young European Investigators This award is a special recognition for our highly motivated research team I am also very thankful for the exceptional support from the IMP and Boehringer Ingelheim our colleagues at the Vienna BioCenter and beyond The award recognises our contributions to revealing the structural mechanisms by which human mRNA is made we look forward to further understanding the molecular processes that regulate how mRNA is made and destroyed." two other finalists were honoured for their exceptional research contributions: Assistant Professor and Group Leader at the Max Perutz Laboratories at the University of Vienna for her work on engineering new strategies for transposon-mediated genetic manipulation and revealing the structural basis for CRISPR-associated transposition The jury noted that Querques' work uncovers new mechanistic insights into site-specific insertion and provides new programmable strategies for targeted genetic modifications PostDoc at the Hubrecht Institute in Utrecht for his research on the molecular and cellular mechanisms underlying heart regeneration Nguyen discovered a detailed sequence of molecular events controlling the disassembly and re-assembly of structural elements in heart muscle enabling cells to proliferate and re-integrate functionally into the injured heart His discovery offers fundamental insights into tissue regeneration biology and identifies new targets for future therapeutic approaches to heart injury The Award Ceremony took place on 27 June 27 2024 at the Advanced Training Center of the European Molecular Biology Laboratory (EMBL) in Heidelberg Visit the Eppendorf website to learn about application modalities selection criteria and previous winners of the Eppendorf Award for Young European Investigators More information online Epidermicin NI01 – an antibiotic compound developed by University of Plymouth spinout company Amprologix – has been shown to be as effective at removin.. Scientists at Vilnius University’s Life Sciences Centre (VU LSC) working with colleagues from the Weizmann Institute of Science in Israel and Harvard Medi.. SETAC Europe ISHM 2025 London Lab Live 2025 Euromedlab 2025 InformEx Zone at CPhl North America SINGAPORE, June 12, 2024 /PRNewswire/ -- NSG BioLabs Singapore's largest provider of biotech co-working laboratory and office space announces a new partnership with Eppendorf a leading international life science company that develops and services for use in laboratories around the world to support biotech startups by providing needed resources such as product and applications expertise and its networks to advance startup research and development (R&D) NSG BioLabs has been assisting innovators in creating impactful solutions in the health working in areas such as precision medicine With the largest co-working biotech laboratory and office footprint in Singapore coupled with extensive networks with local and international partners NSG BioLabs has helped over 40 companies as residents The company's residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones The startup residents alone have successfully raised nearly US$400 million in funding and supported hundreds of jobs "We are thrilled to announce our strategic partnership with Eppendorf a leader in life sciences equipment and services fostering an environment where our residents can thrive is our top priority This collaboration will provide our residents with exclusive access to Eppendorf's cutting-edge equipment empowering them to accelerate their research and scale their innovations we are shaping the future of life sciences and driving impactful discoveries," said Daphne Teo "Empowering innovative biotech startups is of strategic importance to the Eppendorf Group as they drive the future of medical innovation and the development of new treatments Eppendorf's purpose is to help improve human living conditions and we have been clearly committed for almost 80 years in supporting scientists around the world Eppendorf is proud to engage in a partnership with NSG Biolabs affirming its shared vision for supporting innovators in creating impactful biotech solutions Being part of this scientific community is crucial and this collaboration will be the catalyst for transformative breakthroughs in Singapore and beyond," said Surendran Krishnamurthi Managing Director Eppendorf Southeast Asia NSG BioLabs has been supporting biotech startups and multinational companies by providing BSL-2 certified private and shared laboratory spaces and offices as well as privileged access with service providers and suppliers After its first site opening in November 2019 NSG BioLabs expanded with its second site in August 2021 with three sites totaling 35,000 square feet located in the heart of Singapore's R&D ecosystem NSG BioLabs cements its space as a key hub for biotech innovation As one of the largest private biotech incubators in the region coupled with its strong partnerships and strategic investors a life sciences investor set up by Temasek NSG BioLabs is poised to enhance its value-add offerings of infrastructure Eppendorf is a leading international life science company that develops The product portfolio of the business units Liquid Handling & Consumables Separation & Instrumentation and Bioprocess includes ultra-freezers and bioreactors for cell and gene research Eppendorf offers a wide range of high-quality consumables the Eppendorf Group generated €1.08 billion in sales and invested €69 million in research and development (R&D) Eppendorf products are used in academic or industrial research laboratories and industrial laboratories for process analysis the Eppendorf Group has been headquartered in Hamburg and today operates production and R&D sites in Europe Asia and North America and has subsidiaries in 33 countries the Group employs more than 5,000 people worldwide They all act in accordance with the purpose of the company's founders: to improve human living conditions Founded with a focus on supporting biotech innovation NSG BioLabs offers state-of-the-art equipment the expertise of world-class teams and global networks to assist life sciences companies The conducive R&D environment contains fully-equipped certified BSL-2 laboratory and office infrastructure across 35,000 sq ft in the prime location of Biopolis in Singapore.  By providing access to high-quality infrastructure ranging from emerging biotech startups to multinational companies can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients For more information, visit www.nsgbio.com Leading global biotechnology company Amgen Singapore's largest provider of biotech co-working biosafety level 2 laboratories,.. Biotechnology Medical Equipment Medical Pharmaceuticals growing at a CAGR of 4.5% from 2023 to 2030 This comprehensive report provides an in-depth analysis of market trends helping you make informed business decisions The manufacturing and supply of lab consumables have evolved significantly with advancements in technology and materials science Innovations such as automation in production and improvements in design have enhanced the performance and usability of these items modern pipette tips are now designed to reduce the risk of contamination and improve accuracy in liquid handling advancements in sterile packaging and materials used for gloves and other protective gear have greatly enhanced safety standards in labs the integration of sustainability practices like the development of biodegradable or recyclable consumables is becoming increasingly important as laboratories seek to minimize their environmental footprint This evolution reflects a broader trend towards improving lab efficiency and safety while addressing environmental concerns.Key Insights: FOCUS ON SELECT PLAYERS (Total 353 Featured) About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data We provide you with the latest data on international and regional markets The global laboratory centrifuges market size was estimated at USD 1.73 billion in 2023 and is projected to grow at a CAGR of 5.7% from 2024 to 2030 due to advancements in application and increased research activities The increasing demand for personalized medicine and advancements in genomics and proteomics is anticipated to fuel the demand for centrifuge equipment the rise in the prevalence of chronic diseases and increasing developments of advanced products are anticipated to propel the market growth in the coming years.Furthermore technological advancements are anticipated to influence the laboratory centrifuges market over the forecast period Innovations such as automated and high-speed centrifuges have improved efficiency and accuracy The development of compact and user-friendly models has also made these devices more accessible to smaller labs and research facilities advancements in digital interfaces and integration with laboratory information management systems (LIMS) have streamlined operations enhancing productivity and data management Various products are available in the industry with advanced digital interface features digital control interface and high-speed performance for quick nucleic acid and protein separations the availability of such advanced equipment is anticipated to drive the market growth over the forecast period.In addition the increasing focus on research and development (R&D) in the pharmaceutical and biotechnology sectors is anticipated to propel the laboratory centrifuges market Both governments and private entities are investing more in R&D to create new drugs the Minister of Health & Family Welfare introduced the Scheme for Promotion of Research and Innovation in the Pharma MedTech Sector (PRIP) the Department of Pharmaceutical has proposed a PRIP scheme with a budget outlay of USD 598.89 million growing investment in research activities by government bodies is expected to drive the demand for advanced laboratory equipment to support a wide range of experimental and analytical processes.Furthermore the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases is expected to boost the demand for laboratory centrifuges according to data published by the WHO in February 2024 more than 35 million new cancer patients are projected in 2050 a 77% rise from the estimated 20 million patients in 2022.Moreover as per the World Heart Vision 2030 report published by the World Heart Federation cardiovascular disease (CVD) deaths are projected to increase from an estimated 18.9 million in 2020 to more than 22.2 million and 32.3 million in 2030 and 2050 require extensive diagnostic testing and monitoring often involving centrifuges for sample preparation and analysis As the global burden of chronic diseases continues to rise healthcare providers need to expand their diagnostic capabilities thereby driving the need for advanced laboratory equipment This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030 the report has segmented the laboratory centrifuges market report on the basis of product Laboratory Centrifuges Market Analysis ToolsChapter 4 Laboratory Centrifuges Market: Product Estimates & Trend Analysis4.1 Laboratory Centrifuges Market: Product Movement Analysis4.3 Laboratory Centrifuges Market by Product Outlook (USD Million)4.4 Market Size & Forecasts and Trend Analyses Laboratory Centrifuges Market: Model Type Estimates & Trend Analysis5.1 Laboratory Centrifuges Market: Model Type Movement Analysis5.3 Laboratory Centrifuges Market by Model Type Outlook (USD Million)5.4 Laboratory Centrifuges Market: Application Estimates & Trend Analysis6.1 Laboratory Centrifuges Market: Application Movement Analysis6.3 Laboratory Centrifuges Market by Application Outlook (USD Million)6.4 Laboratory Centrifuges Market: Intended Use Estimates & Trend Analysis7.1 Laboratory Centrifuges Market: Intended Use Movement Analysis7.3 Laboratory Centrifuges Market by Intended Use Outlook (USD Million)7.4 Laboratory Centrifuges Market: Regional Estimates & Trend Analysis8.1 Regional Laboratory Centrifuges Market movement analysis8.3 Laboratory Centrifuges Market: Regional Estimates & Trend Analysis by Product is one of the most well-known and widely used laboratory consumables in the world the Eppi was the first single-use microcentrifuge tube to be brought to the market over a billion Eppis have been sold worldwide and the term has become a synonym for microcentrifuge tubes themselves laboratories around the world benefit not just from Eppendorf Tubes® but also the range of compatible Eppendorf lab devices and consumables The launch of the first Eppi allowed scientists to easily handle small volumes manually allowing volumes of expensive reagents and precious samples to be reduced The Eppi also provided solutions for sample mixing helping to fuel amazing discoveries across bioscience within a decade of the first Eppi being manufactured there were major advances in molecular biology with the development of gene cloning and PCR advances include the discovery of life-saving vaccines such as the first hepatitis B and meningitis vaccines creating the need for a range of lab bench devices and consumables that were compatible with this new size of tube Eppendorf developed the microliter system to offer full sample processing solutions for microliter volumes the range consisted of a mixer and centrifuge the microliter system has expanded further and mixers being complemented by Eppendorf Tubes and pipette tips that process sample volumes ranging from 0.2 mL to 50 mL The 60th anniversary of the Eppi tube marks a significant milestone this innovation was a catalyst for the development of a whole range of laboratory consumables that are at the heart of modern lab equipment Eppendorf continues to develop new technologies and products that are designed to improve experimental outcomes and push the boundaries of scientific discovery This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.The global laboratory consumables market is estimated to be USD 15.86 billion in 2024 and is expected to reach USD 39.58 billion by 2035 with a CAGR of 8.67% during the forecast period 2025-2035 The market will be driven by developments in biotechnology and healthcare and growing investments in emerging markets Continued investments in academic research particularly in life sciences and medical fields significantly drive the demand for a wide range of laboratory consumables These products are essential for supporting biomanufacturing the Government of Canada announced a USD 22.25 million investment from the Strategic Innovation Fund to strengthen domestic biomanufacturing supply chains part of a USD 88.21 million project by Pharmascience Inc. reflects a growing emphasis on research and innovation infrastructure further fueling the need for high-quality laboratory consumables across academic and industrial sectors North America is anticipated to have the highest revenue share during the forecast period owing to the well-established research infrastructure significant investments in pharmaceutical and biotechnology R&D and the presence of leading market players driving the demand for laboratory consumables Asia Pacific is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of healthcare and research infrastructure increasing government funding for life sciences research and the growing presence of pharmaceutical and biopharmaceutical manufacturing hubs in countries such as China Haier Biomedical demonstrated its resolve to broaden and improve the scope of smart laboratory solution scenarios in January 2023 when it acquired Suzhou Kangsheng The latest acquisition represents Haier Biomedical's calculated decision to expand the range of smart laboratory application solutions and incorporate disposable laboratory plastic consumables into its business portfolio.By product the vials and containers segment accounted for the highest revenue-grossing segment in the global laboratory consumables market in 2024 This was due to the rising demand for high-quality storage solutions for biological samples and reagents driven by increased research and diagnostic activities globally introduced the newest model in their line of electronic pipettes The Picus 2 sets a new standard for efficiency with its improved connectivity and exceptional performance enabling accurate and repeatable dispensing in quality control and biopharmaceutical applications the pipettes and tips segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of automated liquid handling systems and growing research in molecular biology and genomics.By application the clinical diagnostics segment accounted for the highest revenue-grossing segment in the global laboratory consumables market in 2024 owing to the surge in diagnostic testing due to the rising prevalence of chronic and infectious diseases as well as advancements in diagnostic technologies 3M declared in March 2023 that it will invest USD 146.0 million to increase its capacity in biopharma filtration technology In addition to upgrading facilities and equipment this investment will create 60 full-time jobs at 3M's European manufacturing facilities Particularly noteworthy investments are made in cutting-edge fields including wearable medical technology the pharma & biopharma manufacturing segment is predicted to grow at the fastest CAGR during the forecast period owing to its growing reliance on consumables for quality control and high-throughput screening in drug development.By end-user the academic and research institutes segment accounted for the highest revenue-grossing segment in the global laboratory consumables market in 2024 owing to the continued investments in life sciences and medical research supported by government and private funding which combines Hamilton's cutting-edge CO-RE II technology with ground-breaking air displacement pipetting technology the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period and significant investment in biopharmaceutical innovation.Report Scope Laboratory Consumables Market Analysis & Forecast by Product 2024 - 2035 (Revenue USD Bn) Laboratory Consumables Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn) Laboratory Consumables Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn) For more information about this report visit https://www.researchandmarkets.com/r/ssoptp an Eppendorf Group Company offering a flexible Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN) has entered into a “preferred vendor” partnership with US Lab Partners a strategic consulting and advisory firm that provides life sciences companies with best-in-class labs US Lab Partners engages with life science organizations at various points during the corporate life cycle to provide the infrastructure life sciences companies require to solve complex issues and serve their employees and stakeholders.The partnership ensures that US Lab Partners clients including academic spin-outs and established biotech and pharma companies building new capabilities are equipped with the digital capabilities to support laboratory workflows and other operational necessities alongside the physical facilities and vendor relationships We help our clients develop a roadmap for their project and manage every step of the process using our pre-existing ecosystem of partners,” “Adding eLabNext as a valued member of that ecosystem means that we provide our clients with the best sample and protocol management system available so their research can be as successful as possible.” the team at US Lab Partners has a background in science and we share a strategic vision: To help scientific teams in life sciences achieve their full potential by providing the best solutions in the industry,” states Zareh Zurabyan “This alignment makes us the perfect partners.We’re excited to enhance the efficiency of US Lab Partners’ clients through laboratory digitalization.” eLab Next Posted in: Device / Technology News Please use one of the following formats to cite this article in your essay eLabNext and US Lab partners form strategic partnership to enhance digital infrastructure of emerging and established life science companies 2025 from https://www.news-medical.net/news/20240827/eLabNext-and-US-Lab-partners-form-strategic-partnership-to-enhance-digital-infrastructure-of-emerging-and-established-life-science-companies.aspx "eLabNext and US Lab partners form strategic partnership to enhance digital infrastructure of emerging and established life science companies" <https://www.news-medical.net/news/20240827/eLabNext-and-US-Lab-partners-form-strategic-partnership-to-enhance-digital-infrastructure-of-emerging-and-established-life-science-companies.aspx> https://www.news-medical.net/news/20240827/eLabNext-and-US-Lab-partners-form-strategic-partnership-to-enhance-digital-infrastructure-of-emerging-and-established-life-science-companies.aspx Cancel reply to comment Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab discusses how he is addressing today’s medical challenges using the technology of the future Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening you can trust me to find commercial scientific answers from News-Medical.net please log into your AZoProfile account first Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content A few things you need to know before we start Read the full Terms & Conditions Total revenue: $1,165 million (€1,081 million) APAC revenue: $356 million (€329.7 million) (China+ Asia/Pacific/Africa (APA))  After a successful business performance during the COVID-19 years from 2020 to 2022 revenue in 2023 fell by €152.3 million to $1,165 million or  €1,081.4 million (prior year: $1,333.6 million) reflecting a decline of 12.3 per cent (prior year: +12.1 per cent) The Americas market region experienced a revenue decline of 16.2 per cent in 2023 dropping from $462.8 million to $387.7 million revenue fell from $414 million in 2022 to $393 million in 2023.  the Asia/Pacific/Africa (APA) region faced a decline in customer demand following the coronavirus COVID-19 with revenue dropping by 10.3 per cent from $205 million to $184 million compared to prior year growth of 10.4 per cent This decline was partially offset by robust revenue growth in the Bioprocess unit and the continued success of separation products in Japan and other countries including the opening of a new sales unit in South Africa and the launch of a high-quality consumables portfolio under the Excella brand in the mid-price segment have laid the groundwork for future revenue growth compared to prior year growth of 27.6 per cent particularly in the biopharma and biotech sectors experienced a significant 30 per cent drop in revenue due to a weak business environment marked by low investment and market confidence “The life science industry will continue to grow in the long term the development of global markets in 2024 will remain subject to uncertainty and volatility as well as a number of specific challenges the financial year will again be dominated by cost management budget discipline and savings to improve profitability demand for our products is recovering only slowly so far We expect order intake to stabilise in 2024 and develop- ment for the year as a whole to be at the same level as the previous year.”  MM Activ Singapore Pte Ltd 1 North Bridge Road,#08-08 High Street Centre communications@biospectrumasia.com +65 90150305 Copyright 2025 MM Activ Singapore Pte Ltd Eppendorf has launched the CellXpert CS220 which was developed to speed up mammalian shake flask culture projects and to meet the industry’s increasing need for higher contamination prevention standards The company says that the CellXpert CS220 is the first shaker to apply the established contamination protection standards of CO2 incubator–based cell cultivation—180°C sterilization the company says the device was designed to expedite disinfection by having no drive wheel or heating gins inside its stainless-steel chamber Eppendorf Increasing the efficiency of bioprocess workflows is key to stay competitive The SciVario twin helps to develop and optimize processes in terms of time and cost efficiency All critical process parameters can be precisely controlled directly at the controller's touch screen it is suitable for microbial and cell culture applications The innovative bay-drawer system enables the system to flexibly adapt to unique requirements and changing processes Eppendorf will offer updates with new functional modules and additional software features to make the SciVario twin a future-proof solution To learn more about the SciVario twin and VisioNize, visit:www.eppendorf.com/scivario Contact:Eppendorf AG Bioprocess CenterRudolf-Schulten-Str. 552428 JuelichGermanyTel: +49 2461 980-400E-Mail: bioprocess-info(at)eppendorf.deInternet: www.eppendorf.com/bioprocess Sign up for our newsletter! This issue offers insights into Europe's fight for green solutions for a bioeconomy, antimicrobial resistance and how Europe is preparing for the next pandemic. more ➔ Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … more ➔ The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under … more ➔ The Three R (Replacement, Reduction and Refinement) principles developed over 60 years ago provide a framework for more humane lab animal testing and, more importantly, less of it. A range of in-vitro … more ➔ Antibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends … more ➔ Explore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies. more ➔ Through a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing … more ➔ In 2018, the Hamburg life science company presented its highly prestigious research prize for the 23rd time. The independent Eppendorf Award Jury chaired by Prof Assistant Professor at the Swiss Federal Institute of Technology as the 2018 winner of the Eppendorf Award for Young European Investigators The Award ceremony took place at the EMBL Advanced Training Centre in Heidelberg The laudation honoring Andrea Ablasser’s achievements was held by Award Jury Chairman Prof Reinhard Jahn of the Max Planck Institute for Biophysical Chemistry Andrea Ablasser: “I am greatly honored to receive the prestigious Eppendorf Award It recognizes the contributions of several gifted colleagues and students We are fascinated by the fundamental mechanisms of innate immune recognition that enable defense against pathogens and hope that our research will in the future aid the development of new treatment options for human diseases.” With the Eppendorf Young Investigator Award Eppendorf AG honors outstanding work in biomedical research and supports young scientists in Europe up to the age of 35 The Eppendorf Award is presented in partnership with the scientific journal Nature The Award winner is selected by an independent committee composed of Prof Reinhard Jahn (Max Planck Institute for Biophysical Chemistry Dieter Häussinger (Clinic for Gastroenterology Lohse (Max Delbrück Center for Molecular Medicine in the Helmholtz Association Laura Machesky (Cancer Research UK Beatson Institute receives the € 20,000 prize for her contributions to a key step in the innate immune response which triggers a frontline defense when cells are attacked by microorganisms The Jury: “Andrea Ablasser’s work sheds light on the mechanisms by which other cells are informed about the presence of foreign DNA and she has recently shown that the same pathway can be triggered in ageing cells This work may lead to novel therapeutic approaches for both microbial infections and autoinflammatory syndromes.” Do you use any Eppendorf products in your lab? Write a review today for your chance to win a $400 Amazon voucher! The global bioreactors market is estimated to grow from $16.7 billion in 2024 to $51.7 billion by 2035 representing a CAGR of 11.1% during the forecast period from 2024 to 2035 The global expansion of biopharmaceutical products has led to significant growth in the bioprocessing supplies market this market has consistently grown at an annual rate of between 12 and 14% With companies either establishing their own biopharmaceutical manufacturing facilities or outsourcing production to biologics contract manufacturing organizations (CDMOs / CMOs) the demand for clinical and commercial-scale bioreactors has surged considerably the research suggests that the current bioreactors capacity including the captive and outsourced capacity the bioreactors market has grown to be competitive market with a large number of active companies possessing the expertise to design engineer and manufacture diverse types of bioreactors (in term of design and mechanism of action) for varying applications Some examples of their offerings include stainless steel bioreactors Bioreactors Market Segmentation OverviewMarket Share by Fabrication Material the global bioreactor market is categorized into stainless steel bioreactors single use bioreactors and glass bioreactors The stainless steel bioreactors segment occupies the highest share in 2024 the single use / disposable bioreactors segment is anticipated to show the highest market growth potential during the forecast period This surge in the market is attributed to the increasing demand for emerging biologic modalities such as cell and gene therapy products as well as antibody drug conjugates which require more flexible and smaller-scale production solutions Single use / disposable bioreactors offer quick turnaround times making them ideal for multiproduct facilities in bioprocessing ABEC introduced its 4000-L and 6000-L disposable bioreactors and Thermo Fisher unveiled its 5000-L disposable bioreactor addressing unmet market needs for high volume single use bioreactors which can deliver performance comparable to that of stainless steel bioreactors the bioreactors market is categorized into batch and fed-batch The batch and fed-batch bioreactors segment currently occupies the highest market share and this trend is expected to remain same during the forecast period the continuous bioreactors segment is projected to grow at a relatively higher growth rate during the forecast period Continuous bioprocessing integrates sequential steps are either adopting or contemplating the implementation of continuous bioprocessing technologies including the perfusion bioreactors a developer of the 2 ml continuous perfusion cell culture platform technology enabling scalable perfusion bioreactor processes from 2 ml to 2,000 L with rapid lab-scale process development the bioreactors market is segmented into antibodies the market is dominated by revenues generated from the sales of bioreactors for manufacturing antibodies Antibodies are experiencing rapid growth in the biomanufacturing industry due to their versatility According to the Umabs Antibody Therapies Database over 170 therapeutic antibodies have been approved by at least one regulatory agency in the world whereas several hundred are in development Beyond the traditional monoclonal antibodies these modalities are available / under development in various formats thereby offering tailored approaches to address different diseases and therapeutic challenges contributing to the growing traction of antibodies in the biomanufacturing landscape the global bioreactors market is segmented into North America Europe dominated the bioreactor market and accounted for the largest revenue share in 2024 It is worth noting that the US has the highest count for bioprocessing facilities the Asia-Pacific region is rapidly expanding the number of biomanufacturing facilities The market report features an extensive study of the current market landscape market forecast and future opportunities for the bioreactor manufacturers The market report highlights the efforts of several bioreactor developers engaged in this rapidly growing segment of the biomanufacturing equipment industry Key takeaways of the market report are briefly discussed below Market Landscape Analysis: Bioreactor Manufacturers The bioreactors market landscape features around 250 companies which claim to possess the necessary technical expertise for manufacturing high-quality bioreactors to serve the needs of a wide range of end users The players can either be original equipment manufacturers (OEMs) that produce different components of bioreactors and construction (EPCs) companies that integrate all the equipment designed by OEM engineers into a complete performing system the Asia-Pacific region has emerged as the key hub in this domain featuring the presence of 122 bioreactor manufacturers The demand for high throughput bioreactor systems has led to the establishment of several start-ups in this field which constitute 54% of the overall players engaged in this domain While commercial scale capacity predominates globally nearly 75% of the companies are involved in manufacturing bioreactors for preclinical purposes working with microbiological process for small biotech production facilities Market Drivers Analysis: The Expansion of CMO Services to Encompass a Broader Range of Biopharmaceutical Products is Propelling the Bioreactors Market As biomanufacturing demands substantial capital investment there's a growing trend towards outsourcing various operations to CMOs and CDMOs over 305 biologics contract manufacturers offer diverse services for biologics with outsourcing projected to outpace captive biopharmaceutical growth which initially boosted the bioreactors market due to their role in efficient vaccine production further contribute to the demand for bioreactors the growth of the market is closely linked to the increasing popularity of biosimilars and biobetters particularly following the patent expiration of blockbuster biologics such as Humira (adalimumab) and Rituxan (rituximab) opening up opportunities for biosimilar manufacturers to enter the market as biosimilars and biobetters gain acceptance in the healthcare industry due to their cost-effectiveness and therapeutic advantages the demand for bioprocessing technologies to support the production of these next-generation biopharmaceuticals is likely witness substantial growth Market Trends Analysis: Emphasis on Automation and Sustainability in Bioreactors Market The bioreactors market is witnessing a significant shift towards sustainable practices evident in the development of bioreactors designed to minimize energy consumption This emphasis on sustainability has led to the increased adoption of single use / disposable bioreactors which offer benefits such as a 45% reduction in water and energy consumption and a 40% decrease in initial investment costs two-thirds of clinical bioproduction processes leverage single use components the research suggests that nearly 25% of the bioreactor manufacturers provide single use / disposable bioreactors there is a growing investment by stakeholders engaged in this domain in enhancing bioprocessing efficiency through automation More than 60% of bioreactor manufacturers now offer fully automated bioreactors These are often integrated with digital biomanufacturing technologies like Process Analytical Technology (PAT) systems which enable real-time monitoring and control of critical process parameters (CPPs) like temperature and biomass concentration throughout the bioprocess Cleaning in Place (CIP) and Sterilization in Place (SIP) features are becoming the mainstream requirements in bioreactor specifications owing to the strict guidelines set by GMP and FDA standards The industry is also embracing modular bioreactors that can be configured sequentially or in parallel facilitating comparative studies and parallel experiments with ease and consistency Bioreactors Market Size Analysis: Batch and Fed-batch Holds the Largest Market Share Batch and fed-batch bioprocess currently hold the majority share within the global bioreactors market fed-batch processing has led to an improvement in product titer as well as the molecule's key quality attributes The key players engaged in this domain include Applikon Biotechnology Solida Biotech and Zhengzhou Laboao Instrument Equipment (LABAO) This market report includes an easily searchable excel database of all the bioreactor manufacturers The market research report presents an in-depth analysis of the various companies that are engaged in the bioreactors industry Home » NSG BioLabs announces partnership with Eppendorf Group NSG BioLabs, Singapore’s largest provider of biotech co-working laboratory and office space With the largest co-working biotech laboratory and office footprint in Singapore The company’s residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones The startup residents alone have successfully raised nearly US$400 million in funding and supported hundreds of jobs “We are thrilled to announce our strategic partnership with Eppendorf This collaboration will provide our residents with exclusive access to Eppendorf’s cutting-edge equipment we are shaping the future of life sciences and driving impactful discoveries,” said Daphne Teo “Empowering innovative biotech startups is of strategic importance to the Eppendorf Group Eppendorf’s purpose is to help improve human living conditions and we have been clearly committed for almost 80 years in supporting scientists around the world Being part of this scientific community is crucial and this collaboration will be the catalyst for transformative breakthroughs in Singapore and beyond,” said Surendran Krishnamurthi After its first site opening in November 2019 NSG BioLabs expanded with its second site in August 2021 with three sites totaling 35,000 square feet located in the heart of Singapore’s R&D ecosystem Source TraceLink & Genpact partner to boost digital supply chain in healthcare MTF Biologics and Centurion partner to advance wound care technologies World Business Outlook is a print and online magazine providing comprehensive coverage and analysis of the financial industry, international business and the global economy. Cell and gene therapy (CGT) is becoming a big business It is still relatively young compared to the rest of the biologics industry but the seminal work of Shinya Yamanaka in 2006 to generate induced pluripotent stem cells via cellular reprogramming laid the foundations for the growth in CGT that we observe today Exciting new opportunities to bring life-saving treatments to the world are emerging as we move away from autologous therapies towards more allogeneic applications and processes are needed to render allogeneic therapies reliable and scalable The latest innovations in upstream bioprocessing for CGT are eliminating the need for complex validation procedures reducing regulatory burdens and accelerating manufacturing timelines With the use of artificial intelligence and machine learning to optimize bioprocess parameters and predict outcomes further innovations are just around the corner Vice President of Eppendorf’s Bioprocess Unit based in North Rhine-Westphalia who is in the forefront of bioprocessing innovation for CGT Tao ascended to her current role through marketing and sales positions and clearly knows a thing or two about delivering for customers in the CGT field Allogeneic therapies – riding the crest of a wave Tao reminds us that the first stem cell-based therapy was clinically approved in 2009 marking a significant milestone in the development of CGT she notes the shift from autologous to allogeneic therapies in which healthy donor cells are modified to treat multiple patients rather than tailoring treatments to each individual This has had implications for bioprocessing stem cell and CGT processes have been developed using 2D static systems which sufficed for research primarily focused on autologous applications,” she says “But this allogeneic approach now brings new challenges as the processes need to be standardized and scalable,” she adds 2D static processes utilize plates and flasks that do not provide enough capacity or the expansion capability to cultivate enough cells And that is where Eppendorf’s bioreactor technology comes in Addressing bioprocessing challenges with Eppendorf solutions Eppendorf’s stirred-tank bioreactors are an ideal solution for scale-up operating from a few milliliters up to around 50 liters with single-use solutions “Processes can be tested in small volumes and the technology transfer from small to larger volumes is assisted by appropriate software solutions that calculate the parameter settings needed for a straightforward scale-up process,” Tao explains She further elaborates that the parallel control of multiple bioreactors in Eppendorf systems speeds up process development, fosters standardization, and saves costs – especially when single-use bioreactors such as the BioBLU® system are used “Single-use bioreactors eliminate the need for time-consuming and costly cleaning and sterilization processes associated with traditional stirred-tank bioreactors,” Tao asserts and enables faster turnaround times for production,” she adds Single-use systems also eliminate the need for complex validation procedures the adoption of single-use bioreactors in the CGT industry represents a transformative shift ultimately supporting the commercialization of life-changing therapies,” she says It is apparent that even shear stress-sensitive cells such as stem cells can be cultivated successfully in stirred-tank bioreactors something that Eppendorf have been doing for more than a decade now Their customers are now achieving yields of more than 35 million cells per milliliter 3D-stirred bioreactors – a new ‘gold standard’ 3D-stirred bioreactors with single-use technology will become the new gold standard for CGT upstream bioprocesses we believe that 3D stirred-tankbioreactors with single-use technology will become the new gold standard for CGT upstream bioprocesses due to their superior performance as well as gene transfer and expression,” she says Allied to Eppendorf’s advanced analytics and monitoring tools (and single-use bioreactors) these technologies offer consistent and reproducible manufacturing Staying ahead of the game – a culture of innovation Collaboration with our customers is an essential part of the Eppendorf DNA her team at Eppendorf has many successful examples of collaborations that have advanced bioprocessing in the CGT field “We collaborate with the leading scientists and key opinion leaders in the field to stay at the forefront of innovation We take the approach of listening and understanding our customers’ challenges and pain points and we aim to develop solutions to overcome these challenges and advance their development,” she asserts Robert Zweigerdt at the Hannover Medical School in Germany to develop a special 8-blade impeller optimized for the cultivation of stem cells as aggregates Zweigerdt achieved greater than 35 million cells per milliliter yield after just seven days of cultivation “collaboration with our customers is an essential part of the Eppendorf DNA." Eppendorf’s 70-year history in cell culture bioprocessing and more than a decade of experience in supporting the CGT industry underlines its credentials as a leader in bioprocessing technology development Tao offers some tantalizing thoughts about what the near future may hold in bioprocessing “We expect to see continued advancements in bioprocess automation such as the use of artificial intelligence and machine learning to optimize process parameters and predict outcomes,” she enthuses More discriminating assays and more rigorous research standards are emerging to support applications from disease modeling to therapeutic development Eppendorf’s scalable BioBLU bioreactor portfolio enables 400-fold cell expansion in volumes between 100 mL and 40 L Special BioBLU single-use bioreactor versions have been developed for the distinct requirements of suspension cells Stem cell research recently celebrated its 60th anniversary Although the first publications in this field appeared in the early 1960s it took another 20 years before the first embryonic stem cells could be isolated Another important milestone was passed in 2006 when Kyoto University’s Kazutoshi Takahashi reported that they had used defined factors to reprogram differentiated cells to an embryonic-like state This work led to induced pluripotent stem cell (iPSC) technology that made it much easier to conduct stem cell research This technology not only simplified the procurement of stem cells but it also made it possible to avoid the ethical concerns that attend the use of human embryonic stem cells the first stem cell therapy for the treatment of limbal stem cell deficiency a disease in which a regular corneal epithelium is missing was approved by the European Medicines Agency according to the Alliance for Regenerative Medicine 14 cell and gene therapies available in different markets across the world involve stem cells The intervals between new therapies are becoming shorter and shorter as the technology has matured to the point where clinical application is possible on a larger scale Many established companies are investing heavily because stem cell–derived therapies have great potential to revolutionize medicine New technologies have also enabled the development of startups These companies support the optimization of current production processes and the development of new therapeutic products This article highlights some of the current challenges associated with the development of new stem cell–based therapies and how new technologies are overcoming these challenges Stem cell therapy is a promising option for many diseases particularly those for which cures are lacking stem cell therapy holds promise for the repair of damaged tissue that has very low regeneration potential as stem cells can be transformed through targeted differentiation into any adult tissue that would not have regenerated on its own Tissues that are difficult to replace include lung parenchyma The regeneration of nerve cells in particular holds great potential for the treatment of diseases associated with brain tissue losses MaxWell Biosystems has developed high-density microelectrode arrays to study the function of neurons derived from iPSCs and other neuronal sources Two-dimensional and three-dimensional cell culture systems that mimic in vivo conditions to varying degrees are a valuable substitute for traditional animal models Besides providing a crucial starting point for disease modeling these systems offer significant opportunities for artificial intelligence The technology provides additional information from network to subcellular resolution allowing the recording of axonal signals at unprecedented resolution and quality compared with conventional patch-clamp methods particularly the observation of multiple loci in one measurement new approaches to measuring the properties of individual cells rather than cell populations are being explored in the field of stem cell therapy Some important biological processes are either completely or partially undetectable when tested with standard assays averaged over many cells the latest technologies have enabled researchers to analyze ever smaller systems and even go down to the level of individual cells Bulk tissue sequencing has been replaced by multicell analysis where normal development and disease processes can be studied at single-cell resolution and a link can be made between the cell’s phenotype and its genotype and proteome high-throughput assays provide new and valuable insights into different developmental pathways one must be able to work with very small volumes (down to the picoliter range) and samples Cellenion produces instruments for single-cell dispensing and precise reagent dispensing in small volumes Cells can be dispensed into individual wells by systems that integrate acoustics such systems can sort cell types based on fluorescence signals and distinguish between active and dead cells.) The isolation of single cells is necessary to enable multiple applications including single-cell omics and cell line development One example of a single-cell omics application is the characterization of circulating tumor cells (CTCs) which are thought to be the seeds of metastasis in patients with malignant tumors these cells have the potential for tissue formation and show genomic instability Metastasis of a primary tumor is always associated with a significant worsening of prognosis for cancer patients so it is important to understand how CTCs form metastases and other constituents of isolated CTCs could inform the development of therapies capable of targeting CTCs for destruction or preventing new metastases such therapies could dramatically improve the outcomes for many tumor patients CTCs are extremely rare in peripheral blood (1 in 1011 cells) which makes their isolation from regular blood cells very challenging CTCs can be isolated with single-cell sorting technologies for further studies in a purity that was previously unattainable The manufacture of stem cell–based therapies must be carried out under strict quality controls that satisfy regulatory bodies and ensure the safety of potential patients Such therapies use “living drugs” derived from tissues or cells to treat various diseases advances in cell therapies require that large volumes of high-quality cell collections be produced through high-throughput and traceable bioprocessing systems As the industry moves from autologous to allogeneic cell therapies the single-use bioreactor is becoming the preferred tool for manufacturers who value its ability to improve process control and facilitate scalable production Besides enabling the shift from autologous to allogeneic products single-use bioreactors are enabling another kind of shift the transition from laboratory research to reliable manufacturing They may prove crucial to realizing the full potential of stem cell therapies such as the bioreactors in Eppendorf’s BioBLU series single-use bioreactors eliminate the need for cleaning after each use eliminate the risk of contamination from previous batches Single-use bioreactors also offer noninvasive sensors for temperature This avoids direct contact of the sensors with the medium and further reduces the risk of contamination Eppendorf has also developed tools for process development in cell and gene therapy the company offers miniature bioreactor systems Such systems are intended for statistical design of experiments and the standardization and streamlining of process developments A major problem with iPSCs is their inherent genetic instability which often leads to inconsistent batch quality and represents a major challenge in this field This problem cannot be solved by simply removing contaminants such as bacteria or cells of previous batches but rather must be addressed with cell line development and strict quality control mechanisms To enhance the quality of stem cell research results and protect the reputation of the stem cell field as a whole the International Society for Stem Cell Research has issued a guidelines document Standards for Human Stem Cell Use in Research offered this comment: “[We] will be introducing the checklist for authors that accompanies the guidelines on a trial basis … My colleagues and I feel this is a major step forward in ensuring rigor and reproducibility in all areas of stem cell research.” “These new standards put a lot of pressure on existing developers of stem cell therapies,” notes Annick Marcellin The company offers solutions to many challenges in stem cell research including a range of genomic integrity tests and cell line authentication products The company also specializes in quality control issues in the development and production of stem cell therapies New approaches based on digital PCR enable the detection of the most common genomic abnormalities in iPSCs with a turnaround time of just a few days the company aims to bring improved assays into the market that enable the detection of iPSCs at lower detection limits Stem Genomics’ products also include next-generation sequencing assays that enable a more detailed analysis of cell lines and methods that can screen for common bacterial contaminants such as Mycoplasma species throughout the cell culture life cycle Stem cell therapies have reached a point where they can be used clinically to a limited extent for selected diseases stem cell therapies show promise against type 1 diabetes which affects more than 8 million people worldwide The condition is caused by the destruction of a small but crucial population of cells There are only a few of these cells in healthy people but their destruction can quickly lead to fatal consequences The regeneration of these islet cells through stem cell therapy promises to permanently cure this form of diabetes and drastically improve the quality of life of those affected The technologies that have been presented in this article reflect the current status of stem cell therapy development They are also poised to contribute to the continuous progress that has always characterized the field About us | Advertise with us | Contact us www.eppendorf.com [email protected] Eppendorf is a leading life science company that develops and sells instruments and cell handling in laboratories worldwide Its product range includes pipettes and automated pipetting systems and DNA amplification equipment as well as ultra-low temperature freezers and single-use bioreactor vessels complement the range of highest-quality premium products Eppendorf products are most broadly used in academic and commercial research laboratories in companies from the pharmaceutical and biotechnological as well as the chemical and food industries They are also aimed at clinical and environmental analysis laboratories and at industrial laboratories performing process analysis Germany in 1945 and has about 4.500 employees worldwide The company has subsidiaries in 26 countries and is represented in all other markets by distributors All subscriptions include online membership giving you access to the journal and exclusive content Write for us | Advertise with us European Pharmaceutical Review is published by: Russell Publishing Ltd.Court LodgeHogtrough HillBrasted © Russell Publishing Limited Website development by e-Motive Media Limited Necessary cookies are absolutely essential for the website to function properly This category only includes cookies that ensures basic functionalities and security features of the website These cookies do not store any personal information CookieDescriptioncookielawinfo-checkbox-advertising-targetingThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".cookielawinfo-checkbox-analyticsThis cookie is set by GDPR Cookie Consent WordPress Plugin The cookie is used to remember the user consent for the cookies under the category "Analytics".cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin The cookie is used to store the user consent for the cookies in the category "Necessary".cookielawinfo-checkbox-performanceThis cookie is set by GDPR Cookie Consent WordPress Plugin The cookie is used to remember the user consent for the cookies under the category "Performance".PHPSESSIDThis cookie is native to PHP applications The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website The cookie is a session cookies and is deleted when all the browser windows are closed.viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies It does not store any personal data.zmember_loggedThis session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users Commercial Operations moves from New York to Massachusetts to support continued growth announces that its Americas Market Region Commercial headquarters officially moved from Hauppauge The strategic move is to support continued growth by being in closer proximity to world renowned academic institutions and research centers top pharmaceutical and biotechnology companies and premier hospitals and clinical laboratories covers 14,000 square feet and will have an estimated 50 full time employees This location serves as the home office for American commercial operations including marketing "We are excited to join the Massachusetts life science community," says Dennis Barger "We feel that Framingham's proximity to life science innovators will greatly contribute to our growth strategy by facilitating enhanced collaboration with our customers and greater access to the talent to needed grow our business." The office will be centered around innovation and collaboration There is a show room featuring some of Eppendorf's most popular products and dedicated working areas for visiting colleagues Eppendorf celebrates its 75th anniversary this year and the relocation will help the Americas Market Region continue its deep history supporting scientists About EppendorfEppendorf is a leading life science company that develops and sells instruments Germany in 1945 and has more than 3,600 employees worldwide Media Contact:Kelly Smith [email protected] Kelly Smith[email protected] https://www.eppendorf.com/US-en/ Flavio Donato has been named the 2017 grand prize winner in the annual international competition for The Eppendorf & Science Prize for Neurobiology Curious about the brain's "instruction manual" during development Donato sought to make sense of how the brain's components work together to form a highly functional organ "We must start applying the same technologies developed for the study of adult circuits to developing circuits so that researchers can successfully examine how function emerges from the fascinating orderly mess that is the brain during the first weeks of life Only by integrating the investigation of neural circuit assembly structure and function can we then really have a chance to comprehend how the brain as a whole gives rise to those sophisticated phenomena that make us who we are," Donato said it has been well established that for parts of the brain to mature and establish the specific connections that make cognition possible waves of neural activity must spread from the eyes and nose to the center of the nervous system Sensory experience in young animals is instrumental in this phenomenon and the sensory organs are the source of this developmental signal Seeking additional insight into similar mechanisms at work in other centers of the brain Donato and his team discovered that the signal to develop one area known to be involved in more abstract functions in a specific population of neurons that kicks off the maturation of an entire neural network those cells seemed to be intrinsically programmed to perform this operation since their own maturation likely depended on a clock that started ticking the moment they developed the part of the brain known to function in memory and navigation Researchers have good methods for labeling neurons based on where in the brain they developed but the methods for labeling neurons that develop at the same time are less precise Donato pioneered a strategy that allowed his team to find the neurons responsible for building the entorhinal-hippocampal region targeted toward the developing brains of mice at specific time points The technique allowed him to zero in on and label populations of neurons that develop at the time of labeling without any previous understanding about their identity beyond their birthdate Donato emphasized that this labeling step was key to closely tracking development among a crowd of neurons in addition to manipulating their activity at later stages of life "These experiments opened up a new world to us," Donato said "By observing entorhinal-hippocampal neurons based on their birthdate we realized that these cells were somehow special and very different from the other surrounding cell types which was instrumental to find out how and to what extent they influenced the assembly of the network." Donato's prize-winning essay "Assembling the brain from deep within," highlights how his results have important implications in degenerative brain disorders such as Alzheimer's disease "Many neurological conditions seem to target specific populations of neurons that are more susceptible than others to molecular events underlying the pathology," he wrote one of the first cell types affected by the pathology is one that we've observed to play a leading role in the development of the entorhinal-hippocampal network." Donato believes that further investigation may someday give scientists the ability to "slow down or even rescue the deficits that such pathologies produce in the brain." Knowing how these cells mature during development might lead to a better grasp of just how to replicate that process in the adult brain which could eventually pave the way to strategies that rejuvenate aging circuits "Flavio Donato investigated a critical aspect of circuit maturation in the developing brain," said senior Science editor Peter Stern and his meticulous attention to detail that helped him win this year's prize." who is currently completing his postdoctoral fellowship at the Norwegian University of Science and Technology said next steps will involve delving into the "early-life dynamics necessary for the production of circuits that represent space in the brain and help humans create memories of life's everyday events." Donato and the following finalists will be recognized at a prize ceremony in conjunction with the Annual Meeting of the Society for Neuroscience The ceremony will be held at Science/AAAS Headquarters in Washington D.C for her essay "Overriding sleep." Gradinaru received her undergraduate degree from the California Institute of Technology and her Ph.D Gradinaru and her research group are developing technologies for neuroscience and using them to probe circuits underlying locomotion for his essay "Sleep on it." Diering received his bachelor's and doctorate degrees at the University of British Columbia Diering characterized changes in synapse composition that occur during sleep Now an assistant professor at the University of North Carolina Diering's laboratory focuses on the role of sleep in neural development spectrometers and DNA amplification equipment as well as ultra-low temperature freezers microliter plates and single-use bioreactor vessels complement the range of highest-quality premium products forensics and at industrial laboratories performing process analysis Germany in 1945 and has about 3000 employees worldwide [Credit for related image: Alan Simpson/ Flickr] Eppendorf India and Rajalakshmi Engineering College Chennai have signed the extension of the existing Memorandum of Understanding (MoU) in setting up a framework to enable mutually beneficial and collaborative engagements in trainings to improve scientific research and development in the field of Biotechnology Eppendorf is committed to skill development by offering tailor made training programmes for graduate students of Biotechnology Eppendorf India training facility in Chennai includes state-of-the-art laboratories as well as conference and classroom facilities A team of experts at Eppendorf would conduct the trainings on various modules such as Liquid Handling Extraction & Quantification of Biomolecules and PCR technique Training includes intensive sessions with balanced theoretical and hands-on modules ensuring the participants gain proficiency communications@mmactiv.com Copyright 2025 MM Activ Sci-Tech Communications Forgot your password? the Hamburg based life sicences company Eppendorf SE is  awarding its prestigious research prize for the 29th time The independent  jury chaired by Prof Austria as the winner  of the Eppendorf Award for Young European Investigators 2024.  receives the 20,000 euro award for his  research on the molecular machines that generate and export messenger  RNA The award is given in recognition of his ground-breaking discoveries  revealing the mechanisms by which messenger RNA is produced and  matured mRNA production involves multiple complex cellular machines that  process and guide the maturation and ultimate export of mRNA from the  nucleus to the cytoplasm.  “Plaschka’s structural and mechanistic investigations have revealed  fundamental insights into how cells express genes and his work has  implications for human diseases involving mutations in core mRNA  processing machines” Clemens Plaschka: „I am absolutely delighted to receive the 2024 Eppendorf  Award for Young European Investigators This award is a special recognition  for our highly motivated research team whose efforts have made this  possible I am also very thankful for the exceptional support by the IMP and  Boehringer Ingelheim our colleagues at the Vienna BioCenter and  beyond The award recognizes our contributions to  reveal the structural mechanisms by which a human mRNA is made we look forward to further  understanding the molecular processes that regulate how mRNA is made and  destroyed.“ In addition to the winner of the Eppendorf Award 2024 Assistant Professor and Group Leader at the Max Perutz  Laboratories at the University of Vienna is honored for her work on  engineering new strategies for transposon-mediated genetic manipulation  and on-revealing the structural basis for CRISPR-associated transposition.  "Querques' work not only uncovers new mechanistic insight into how these  mobile units enable site-specific insertion but also provide new  programmable strategies for targeted genetic modifications," said the jury.  is honored for  his research on the molecular and cellular mechanisms underlying heart  regeneration He discovered a detailed sequence of molecular events that  controls the disassembly and re-assembly of structural elements in the heart  muscle which allows the cells to proliferate and functionally re-integrate into  the injured heart The jury noted that his discovery provides fundamental  insight into the biology of tissue regeneration and identified new targets for  future therapeutic approaches to heart injury.  2024 at the Advanced Training  Center of the European Molecular Biology Laboratory (EMBL) in Heidelberg,  Germany.  Further information on application modalities selection criteria and previous winners of the  Eppendorf Award for Young European Investigators can be found at   With the Eppendorf Award for Young European Investigators which was established in 1995,  Eppendorf SE honors outstanding work in biomedical research and supports young scientists  in Europe up to the age of 35 The Eppendorf Award is presented in partnership with the  scientific journal Nature The Award winner is selected by an independent committee  composed of Laura Machesky (University of Cambridge Sadaf Farooqi (Wellcome-MRC  Institute of Metabolic Science Madeline Lancaster (MRC Laboratory of  Molecular Biology UK;  Center for Genomic Regulation PRBB Stefan Raunser (Max-Planck Institut für Molekulare Physiologie Dortmund) und Michael Sixt (Institute of Science and  Technology Austria ISTA Eppendorf has launched the first centrifuge on the market to be deemed sustainable under the My Green Lab ACT label and how it plays into wider sustainability goals bioprocess vendor and lab suppler Eppendorf said last month its microcentrifuge with hydrocarbon cooling product ‘Centrifuge 5427 R’ is the first centrifuge to be awarded ACT label certification The ACT (Accountability, Consistency, Transparency) label is an accreditation scheme launched by non-profit My Green Lab in 2017 aimed at providing industry transparency about the environmental impact and recyclability of lab equipment so we spoke with Eppendorf to understand what such accreditation really means and how it fits in with continued sustainability efforts Eppendorf: Eppendorf proudly supports sustainability aspects in the laboratories for many years Based on our longterm-cooperation with My Green Lab since 2017 we decided to expand the portfolio of ACT-labeled products at My Green Lab After ULT (Ultra Low Temperature) freezers and manual pipettes we now received the ACT label for the first centrifuge worldwide In close relationship with the My Green Lab team we analyse new product groups for the ACT label Due to our longterm experience with many different product groups at Eppendorf we want to support the ACT label to expand the range of products with ACT label we also received the ACT label for our CombiTips advanced recently Eppendorf: The ACT program is – to our knowledge – the only global program for laboratory equipment which addresses sustainability aspects and product life aspects we were just a very small group of suppliers supporting My Green Lab most of the bigger suppliers of lab equipment participate and label products by ACT many pharma accounts are asking for ACT labeled products and also academic accounts are interested ACT is an independent third-party organization providing user some independent validation of lab products Eppendorf: Every new validation system requires some experience and adaptions As Eppendorf is used to validations due to its ISO certifications of 9011 and 14001 there are some information about the products which required some more work as they were not documented in a way that My Green Lab was able to benefit from it we improve and optimize the process of data collection internally Due to the close interaction with My Green Lab all open tasks can easily be discussed until both parties have a common understanding Eppendorf: The transformation of the company to become greener and more sustainable is a journey we already started with this concept in 1945 when our founders stated their vision ‘to improve human living conditions.’ Similar to this we focused on ergonomic design of our products already at least 20 years ago (PhysioCare concept) hydrocarbon based cooling was launched 2008 by our freezer team there was a growing focus on classic sustainability topics This includes the launch of our biobased tubes in summer 2022 as well as the change to 100% green contract power in all our factories (except Japan) Our goal to cut the carbon emissions in our own operations until 2028 is a challenging target for the next months and years Our customers appreciate this continuous adaption of Eppendorf Eppendorf: We will continue to improve our sustainability aspects we will launch our first hydrocarbon-based refrigerated centrifuge We will expand our biobased consumable portfolio All these new steps require close interactions with our stakeholders This journey can only be done in cooperation Journalist covering the international biopharmaceutical manufacturing and processing industries.Founder and editor of Bioprocess Insider a daily news offshoot of publication Bioprocess International with expertise in the pharmaceutical and healthcare sectors regulatory affairs and business development.From London UK originally but currently based in Montpellier France through a round-a-bout adventure that has seen me live and work in Leeds (UK) CSL Seqirus signs pandemic preparedness plan with European Commission Ins & Outs: Biopharma players shuffle c-suite ranks American made: Companies continue to emphasize US manufacturing Transforming Protein Production: Lonza’s Comprehensive Solutions for Therapeutic Innovation Registered in England & Wales with number 01835199 Steady growth in demand for its bioreactor systems has led Eppendorf to expand its site in Jülich Germany through the addition of a 3,600 m² facility The final construction phase of the three-story building began last week which once operational will more than double production space and increase production capacity by 20% at Eppendorf’s site “The new building offers significantly increased production space for manufacturing bioprocess controllers with the corresponding accessories,” said a spokesperson from the bioprocess vendor software for controlling the devices are developed and set up there.” Among the bioprocess technologies manufacturedat Jülich are the DASbox 2.0 and DASGIP bioreactor systems The former is a mini bioreactor system targeted at small working volumes in research and early process development projects while the latter are designed to deliver optimal bioprocess performance in benchtop configurations demand for such systems has been growing steadily wordwide “With the expansion of the site in Jülich and the new multifunctional building for €12.5 million [$12.5 million] we are responding to this ongoing development The construction project is a commitment to the site and a sustainable safeguard for our production there The growing Bioprocess business of Eppendorf will also create more jobs.” They added that while demand for COVID-19 related products is on the decline it was the pandemic that further drove the expansion as it showed how much Eppendorf and its products were needed “This will continue to be the case in the future With the new building and the capacity growth we are strengthening Eppendorf and our Bioprocess business.” Glial cells are considered support cells in the brain and help control and safeguard neurons The goal of Scavuzzo’s research is to understand the role of enteric glia in a healthy gut and how they respond to dietary Her research could lead to the development of novel and efficient medicines that may benefit millions of people with gastrointestinal illnesses Gray Fellow in the School of Medicine’s Department of Genetics and Genome Sciences “I am grateful to Eppendorf and Science for their recognition of my work and will be forever grateful to my postdoctoral mentor who played a crucial role in fostering my research in his lab My long-term research goal is to understand the molecular underpinnings of enteric glia’s functional states in both health and disease.” professor of genetics and genome sciences and the Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at School of Medicine “I am so proud of her for receiving this prestigious award that recognizes her groundbreaking science.” the annual Eppendorf & Science Prize for Neurobiology has honored early-career scientists for groundbreaking research Scavuzzo is the 22nd recipient of this international prize which is awarded jointly by the journal Science and Eppendorf SE a leading Germany-based life-science company that develops makes and sells systems for use in laboratories worldwide Researchers age 35 and younger who have made outstanding contributions to neurobiological research based on methods of molecular and cell biology are invited to apply The winner is awarded $25,000 and is able to publish an essay published in Science “Eppendorf and the journal Science have awarded this prestigious prize for over 20 years Many awardees have gone on to become leading scientists in their field,” said Alex Jahns Eppendorf’s vice president of corporate citizenship and governmental affairs “Congratulations to Marissa on her amazing achievement in winning this year’s award.” “The support from the School of Medicine has been critical to the success of my research,” Scavuzzo said “and continued collaborations with colleagues will help advance my work towards my goal in the future.” For more information, contact Patty Zamora at patty.zamora@case.edu Subscribe to The Daily Items that appear in the Community Postings section are submitted by visitors Posts are reviewed to ensure they are appropriate for our audience but typically are not edited by University Marketing and Communications Case Western Reserve University is committed to academic freedom and promoting diversity of thought The views of those who speak on our campus do not necessarily reflect the views of the university administration or any other segment of the university community